Floatz logo

[177lu]lu-akir001

Cervix Carcinoma

Karolinska University HospitalradiopharmaceuticalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

60 Active assets in the Cervix Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Advenchen Laboratories, LLC
Phase 3BB
Gardasil 9 Vaccine
Eunice Dube
Phase 4BB
Hepatitis B Virus Vaccine
Eunice Dube
Phase 4BB
Hycamtin
Advenchen Laboratories, LLC
Phase 3BB
Pembrolizumab
Mayo Clinic
Phase 2BB

View all 50 →

Same molecule, other indications

[177lu]lu-akir001 is also rated in:

thyroid gland undifferentiated (anaplastic) carcinomaDormant
C
Indicative ·
39 / 100
View asset →
poorly differentiated thyroid gland carcinomaDormant
C
Indicative ·
39 / 100
View asset →
head and neck cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →